EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Cardiac surveillance in the era of Duvyzat: do we need to do more?

Marika Pane, Anna Capasso, Chiara Arpaia, Romina Venditti, Emilio Albamonte, Rossella D'Alessandro, Federica Ricci, Adele D'Amico, Michela Catteruccia, Michele Tosi, Federica Trucco, Chiara Panicucci und 14 weitere

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases · 01.12.2025 · 44 (4) · 135-137

DOI: 10.36185/2532-1900-1886 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases, erschienen am 01.12.2025. Verfasst von Marika Pane und 25 weiteren Autor:innen. Beteiligte Einrichtung: Centro Clinico NeMO, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy and Pediatric Neurology, Università Cattolica del Sacro…. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is an X-linked recessive neurodegenerative disorder. In the last two decades, there have been several clinical trials with therapeutic approaches targeting different steps of the mechanisms underlying DMD1. One of these approaches uses Duvyzat (givinostat), a histone deacetylase inhibitor that has recently been approved for ambulant DMD boys aged ≥6 years, regardless of genetic mutation2. Since the drug became available in some countries, new safety data have become available mainly confirming the safety profile emerged from both phase 2 and 3 clinical trial2. The safety profile remained acceptable: platelet count reduction, diarrhea, and elevated triglycerides remain the major concerns, the first two primarily occurring in the first months and the increased triglycerides also in the second trimester after treatment is started. More recently, following the availability in a much larger cohort in the real world, there has been some concern about the possible effect on the QT interval on EKG that had previously been found to be prolonged only in preclinical studies at much higher doses than those used in clinical practice. The QT interval had been thoroughly investigated in both clinical trials with no evidence of prolongation, but the question remains whether this holds true in a real world setting where other factors may contribute to produce an abnormal QT interval. As prolonged QT is a major cause of sudden death in young people, and DMD in itself implies an increased risk of malignant cardiac arrhythmias compared to the general population, maintaining a close surveillance on this aspect is paramount. This information has led to a discussion in the clinical community of whether a more accurate surveillance should be used. In Italy, a panel of clinical experts in DMD organized several meetings also involving cardiologists with specific expertise in the study of the QT interval in order to identify possible other factors that may contribute to prolong the QT. Several elements that until now have not been systematically explored, have been now identified. These include QT baseline values below 500 ms but above 450 ms, a difference of 40-50ms from baseline EKG, subclinical low potassium blood level ( 150x 109 and QT interval < 500 ms. The suggestion from our group, in agreement with specialist cardiologists was that it could be useful to collect additional information at baseline that would allow to better understand the risk of developing prolongation of QT interval irrespective of Duvyzat. These would allow us to identify different groups based on a low-, moderate- or high-risk of developing prolonged QT intervals. Based on these criteria, the follow-up after baseline should be shaped accordingly (Fig. 1). Particular attention was also paid to the possibility that these events may occur at any time during long-term therapy, in relation to intercurrent episodes that may cause potassium reduction (e.g., vomiting) or to the introduction of any drug that may prolong QT. Because of this, there was a suggestion that a 24-hour-12-lead Holter EKG should be repeated in the presence of these events to evaluate the possible impact on the QT. While there is no evidence from real-world data that Duvyzat may affect QT, we suggest that at the time the drug will be given at a rapidly increasing number of DMD individuals worldwide more attention should be paid to identify possible concomitant risk factors. A more detailed monitoring plan, as suggested in this letter, may help to obtain a more precise profile of the possible occurrence and severity of QT prolongation in individuals receiving Duvyzat over long-term treatment courses.

Schlagwörter

cardiac surveillance

Autor:innen und Institutionen

  • Centro Clinico NeMO, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy and Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • The NeMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.
  • Child Neuropsychiatry Unit, Department of Public Health and Paediatric Sciences, University of Turin, Turin, Italy.
  • Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Center of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Fondazione IRCCS Istituto Neurologico Carlo Besta, Developmental Neurology Unit, Milan, Italy.

Zitieren

APA

Pane, M., Capasso, A., Arpaia, C., Venditti, R., Albamonte, E., D'Alessandro, R., Ricci, F., D'Amico, A., Catteruccia, M., Tosi, M., Trucco, F., Panicucci, C., Masson, R., Dosi, C., Parravicini, S., Sframeli, M., Bello, L., D'Angelo, M. G., Magri, F., …, & Mercuri, E. (2025). Cardiac surveillance in the era of Duvyzat: do we need to do more?. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases, 44(4), 135-137. https://doi.org/10.36185/2532-1900-1886

Vancouver

Pane M, Capasso A, Arpaia C, Venditti R, Albamonte E, D'Alessandro R, et al. Cardiac surveillance in the era of Duvyzat: do we need to do more?. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases. 2025;44(4):135-137. doi:10.36185/2532-1900-1886

BibTeX
@article{Pane2025,
  author = {Pane, Marika and Capasso, Anna and Arpaia, Chiara and Venditti, Romina and Albamonte, Emilio and D'Alessandro, Rossella and Ricci, Federica and D'Amico, Adele and Catteruccia, Michela and Tosi, Michele and Trucco, Federica and Panicucci, Chiara and Masson, Riccardo and Dosi, Claudia and Parravicini, Stefano and Sframeli, Maria and Bello, Luca and D'Angelo, Maria Grazia and Magri, Francesca and Messina, Sonia and Nigro, Vincenzo and Bruno, Claudio and Comi, Giacomo and Sansone, Valeria Ada and Crotti, Lia and Mercuri, Eugenio},
  title = {Cardiac surveillance in the era of Duvyzat: do we need to do more?},
  journal = {Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases},
  year = {2025},
  volume = {44},
  number = {4},
  pages = {135--137},
  doi = {10.36185/2532-1900-1886}
}
Kostenlos starten →